A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Cancer|Carcinoma, Renal Cell|Lymphoma|Ovarian Cancer
Interventions: DRUG: PSC 833|DRUG: paclitaxel
Sponsor: National Cancer Institute (NCI)